-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$22.67455.64% Upside
Inovio Pharmaceuticals, Inc. Frequently Asked Questions
-
What analysts cover Inovio Pharmaceuticals, Inc.?
Inovio Pharmaceuticals, Inc. has been rated by research analysts at RBC Capital, Oppenheimer, Stephens in the past 90 days.